Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 11Active not recruiting 4Suspended 2Not yet recruiting 2Withdrawn 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Other hematologic neoplasm 1

Conditions

Mesothelioma, Malignant 1Mesothelioma 1Leukemia, Myeloid, Acute 1

Interventions

Specimen Handling 21Biopsy 14Magnetic Resonance Spectroscopy 13Cyclophosphamide 4Nivolumab 3Cetuximab 3Azacitidine 3venetoclax 2trastuzumab deruxtecan 2decitabine and cedazuridine drug combination 2X-Rays 2Vincristine 2Taxes 2Surgical Procedures, Operative 2Standard of Care 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Radiation 2Prednisone 2Practice Guidelines as Topic 2Lenalidomide 2Ipilimumab 2Etoposide 2Doxorubicin 2CTLA-4 Antigen 2(225)Ac-DOTA-c(RGDyK) 2spartalizumab 1relatlimab 1prednylidene 1olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Suspended × decitabine and cedazuridine drug combination × 30 days × Clear all
NCT06802523 2026-05-13

Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 1 Suspended
53 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05960773 2026-05-04

Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma

National Institutes of Health Clinical Center (CC)

Phase 2 Suspended
9 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡